Please assess the completion status of the following clinical trial:

Trial Title: Tacrolimus to Sirolimus Conversion for Delayed Graft Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age =\> 18.~2. Recipient of a deceased donor kidney transplant.~3. Delayed graft function, defined as need for dialysis during first week after surgery or slow graft function, defined as creatinine \>=3.0 by post-op day 5 without requiring dialysis~4. Stable serum creatinine for 2 weeks prior to enrollment.~5. Able to give informed consent.~6. Compliant with medical regimen and clinic visits.~Exclusion Criteria:~1. Episode of acute rejection within 4 weeks prior to enrollment.~2. Calculated GFR \< 30 ml/min.~3. Interstitial fibrosis \& tubular atrophy in transplant biopsy higher than grade II (Banff05 update).~4. Proteinuria \> 500 mg/24 h or spot urine protein/creatinine \> 0.5.~5. Total fasting cholesterol level \> 300 mg/dl or triglyceride \> 500 mg/dl despite optimal lipid lowering therapy.~6. Recipient of pancreas or liver allografts.~7. Leukopenia (WBC \< 3000 mm3) within 2 weeks prior to enrollment.~8. Leukopenia (WBC \< 2000 mm3) within 4 weeks prior to enrollment.~9. Thrombocytopenia (platelets count \< 100,000/mm3) within 2 weeks prior to enrollment.~10. Unwilling to comply with study protocol.~11. Enrollment in another drug trial that precludes use of sirolimus.~12. Diagnosis of malignancy within 2 years prior to enrollment, except adequately treated non-melanoma skin cancer.~13. For women, pregnancy.~14. Allergy to iodine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus (Type: ACTIVE_COMPARATOR): Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
- Sirolimus (Type: ACTIVE_COMPARATOR): 5 mg, PO , daily

Based on this trial design, predict the completion outcome and termination type (if applicable).